Barrett's oesophagus and oesophageal adenocarcinoma

W. Keith Tan,Anjui Wu,Massimiliano di Pietro
DOI: https://doi.org/10.1016/j.mpmed.2023.12.008
IF: 1.6
2024-01-01
Medicine
Abstract:Barrett's oesophagus (BO) is an intestinal metaplastic change of the oesophageal mucosa that typically occurs in response to gastro-oesophageal acid reflux. BO is the only recognized precursor to oesophageal adenocarcinoma (OAC), which has dramatically increased in incidence in the Western world over the past four decades. Currently, upper gastrointestinal endoscopy is the gold standard to diagnose BO, but newer and less invasive screening modalities (e.g. office-based transnasal endoscopy, non-endoscopic cell collection devices, breath testing) are emerging as alternatives. The transition from BO to OAC occurs through intermediate pre-invasive neoplasia (low- and high-grade dysplasia). This sequence provides a clinical opportunity for endoscopic surveillance to detect pre-invasive and early invasive neoplasia. However, diagnosis of dysplasia and stage I cancer poses clinical challenges because of their subtle endoscopic features, which can be more effectively recognized using chromoendoscopic techniques. Dysplasia and early cancer can be cured with minimally invasive endoscopic interventions such as endoscopic ablation and endoscopic resection. The mainstay of treatment of stage II/III OAC is radical oesophagectomy, and recent advances in oncological therapies have improved survival of patient with invasive cancer. In future, molecular risk stratification could allow the identification of patients with BO at higher risk of progression, who could be the target of more proactive therapeutic approaches, and meanwhile follow-up of those at lower cancer risk could be de-escalated.
medicine, general & internal
What problem does this paper attempt to address?